Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.
Sychev DA, Zastrozhin MS, Miroshnichenko II, Baymeeva NV, Smirnov VV, Grishina EA, Ryzhikova KA, Mirzaev KB, Markov DD, Skryabin VY, Snalina NE, Nosikova PG, Savchenko LM, Bryun EA. Sychev DA, et al. Among authors: bryun ea. Drug Metab Pers Ther. 2017 Sep 26;32(3):129-136. doi: 10.1515/dmpt-2017-0021. Drug Metab Pers Ther. 2017. PMID: 28787271
Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.
Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA. Zastrozhin MS, et al. Among authors: bryun ea. Pharmgenomics Pers Med. 2018 Jun 29;11:113-119. doi: 10.2147/PGPM.S160763. eCollection 2018. Pharmgenomics Pers Med. 2018. PMID: 29988737 Free PMC article.
Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder.
Zastrozhin MS, Antonenko AP, Nesterenko EV, Seyfullaeva LI, Mustafina VR, Esakova AP, Grishina EA, Sorokin AS, Skryabin VY, Savchenko LM, Bryun EA, Sychev DA. Zastrozhin MS, et al. Among authors: bryun ea. Drug Metab Pers Ther. 2018 Dec 19;33(4):187-194. doi: 10.1515/dmpt-2018-0019. Drug Metab Pers Ther. 2018. PMID: 30325732
Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers.
Zastrozhin MS, Sorokin AS, Agibalova TV, Grishina EA, Antonenko AР, Rozochkin IN, Duzhev DV, Skryabin VY, Galaktionova TE, Barna IV, Orlova AV, Aguzarov AD, Savchenko LM, Bryun EA, Sychev DA. Zastrozhin MS, et al. Among authors: bryun ea. Hum Psychopharmacol. 2018 Nov;33(6):e2677. doi: 10.1002/hup.2677. Epub 2018 Oct 25. Hum Psychopharmacol. 2018. PMID: 30357930
How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?
Skryabin VY, Zastrozhin MS, Torrado MV, Grishina EA, Ryzhikova KA, Shipitsyn VV, Galaktionova TE, Sorokin AS, Bryun EA, Sychev DA. Skryabin VY, et al. Among authors: bryun ea. Drug Metab Pers Ther. 2020 Mar 5;35(1):/j/dmdi.2020.35.issue-1/dmpt-2019-0026/dmpt-2019-0026.xml. doi: 10.1515/dmpt-2019-0026. Drug Metab Pers Ther. 2020. PMID: 32134726
CYP3A subfamily activity affects the equilibrium concentration of Phenazepam® in patients with anxiety disorders and comorbid alcohol use disorder.
Zastrozhin MS, Skryabin VY, Sorokin AS, Petukhov AE, Smirnov VV, Pankratenko EP, Grishina EA, Ryzhikova KA, Panov AS, Savchenko LM, Bryun EA, Sychev DA. Zastrozhin MS, et al. Among authors: bryun ea. Pharmacogenomics. 2020 May;21(7):449-457. doi: 10.2217/pgs-2019-0071. Epub 2020 Apr 27. Pharmacogenomics. 2020. PMID: 32336193
43 results